There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...

Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

Neela Bhagwat’s music bore the mark of a searching, scholarly mind. As Shubha Mudgal observes, her art never existed in ...

Learn more AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, ...

Investing.com -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares fell 10% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...

MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare penny stocks to buy according to hedge funds. On March 30, ...

India’s R&D needs faster, predictable approval timelines to boost investor confidence: Dr Jogin Desai: Our Bureau, Bengaluru Friday, April 17, 2026, 15:30 Hrs [IST] India’s re ...